If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
IPO today
KE Holdings Inc. (BEKE)
RedBall Acquisition Corp. (RBAC.U)
Upcoming IPO
Vistas Media Acquisition (VMACU)
Hitek Global (HKIT)
Presidio Property Trust (SQFT)
PainReform (PRFX)
PaxMedica (PXMD)
NavSight Holdings (NSH.U)
dMY Technology Group II (DMYD.U)
Duck Creek Technologies, Inc. (DCT)
CureVac B.V. (CVAC)
Dragoneer Growth Opportunities (DGNR.U)
Northern Genesis Acquisition (NGA.U)
Inhibrx, Inc. (INBX)
Harmony Biosciences Holdings, Inc. (HRMY)
Priced IPO
IBEX Holdings Limited (IBEX)
Checkmate Pharmaceuticals, Inc. (CMPI)
Freeline Therapeutics Holdings plc (FRLN)
Rocket Companies, Inc. (RKT)
Oak Street Health, Inc. (OSH)
Acutus Medical Inc (AFIB)
Rackspace Technology, Inc. (RXT)
BigCommerce Holdings, Inc (BIGC)
Fathom Holdings (FTHM)
Vital Farms, Inc. (VITL)
Vasta Platform Limited (VSTA)
AlloVir, Inc. (ALVR)
Li Auto Inc. (LI)
Vertex, Inc. (VERX)
iTeos Therapeutics, Inc. (ITOS)
Inozyme Pharma, Inc. (INZY)
Annexon, Inc. (ANNX)
Nurix Therapeutics, Inc. (NRIX)
Montrose Environmental Group, Inc. (MEG)
Skillful Craftsman Education Technology Ltd. (EDTK)
More companies

Pliant Therapeutics, Inc. (PLRX)

Sector - Healthcare

Price chart

Company News

IPO Profile

About company

They are a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Their initial focus is on treating fibrosis by inhibiting integrin-mediated activation of TGF-ß. Their wholly-owned lead product candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins that they are developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. They have completed a Phase 1a SAD/MAD trial and a Phase 1b proof-of-mechanism trial of PLN-74809 in IPF and are recruiting two Phase 2a trials in IPF. They submitted an investigational new drug application, or IND, for PLN-74809 for the treatment of PSC in March of 2020, and plan to initiate a Phase 2a PSC trial in the second half of 2020, when it is feasible to do so in light of the COVID-19 pandemic. Their second product candidate, PLN-1474, is a small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with NASH, which they have partnered with Novartis. PLN-1474 is currently undergoing a Phase 1 trial with top-line data expected by the end of 2020, subject to the impact of the COVID-19 pandemic. In addition to their clinical programs, they currently have preclinical integrin-based programs targeting oncology and muscular dystrophies.
Bernard Coulie Keith Cummings
Employees Founded
62 2016


Address: 260 Littlefield Avenue, South San Francisco, CA 94080, US

Telephone: (650) 481-6770

Web page:

IPO information

Expected Date 6/3/2020
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
Share prices ($)

Financial Data (last reporting year)

Market Cap (MM) $547.2
Revenues (MM) $85.99
Net Income (Loss) (MM) $8.5


What do you think will happen with the PLRX share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
Shares Initial (MM) 6
Shares Revised (MM) 9
Expected offer amount (MM) $90
Realized offer amount(MM) $144
Citigroup/ Cowen/ Piper Sandler
Needham & Company

Sector: Healthcare

Tweets about $PLRX

Tweets volume:

RT volume:


Google Trends Stats